MorphoSys AG (WBO:MOR) Debt-to-EBITDA : 2.88 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is MorphoSys AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

MorphoSys AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €14.1 Mil. MorphoSys AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €621.9 Mil. MorphoSys AG's annualized EBITDA for the quarter that ended in Dec. 2023 was €220.5 Mil. MorphoSys AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 2.88.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for MorphoSys AG's Debt-to-EBITDA or its related term are showing as below:

WBO:MOR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -12.44 Med: 0 Max: 6.26
Current: -12.44

During the past 13 years, the highest Debt-to-EBITDA Ratio of MorphoSys AG was 6.26. The lowest was -12.44. And the median was 0.00.

WBO:MOR's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.375 vs WBO:MOR: -12.44

MorphoSys AG Debt-to-EBITDA Historical Data

The historical data trend for MorphoSys AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Debt-to-EBITDA Chart

MorphoSys AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.43

6.26

-0.63

4.83

-9.02

MorphoSys AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															0.86	-5.24	-1.72	-	2.88

Competitive Comparison of MorphoSys AG's Debt-to-EBITDA

For the Biotechnology subindustry, MorphoSys AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MorphoSys AG's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MorphoSys AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's Debt-to-EBITDA falls into.

MorphoSys AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

MorphoSys AG's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(14.051	+	621.882)	/	-70.528
	=	-9.02

MorphoSys AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(14.051	+	621.882)	/	220.544
	=	2.88

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

MorphoSys AG (WBO:MOR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

MorphoSys AG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (WBO:MOR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (WBO:MOR) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

MPSYF:USA MOR:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.